Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy

详细信息    查看全文

• 作者：Yasuyuki Kinoshita ; Atsushi Tominaga ; Satoshi Usui ; Kazunori Arita…
• 关键词：Growth hormone ; Insulin ; like growth factor ; 1 ; Acromegaly ; Discordance ; Natural history
• 刊名：Neurosurgical Review
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：39
• 期：2
• 页码：313-319
• 全文大小：514 KB
• 参考文献：1.Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A Consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148CrossRef PubMed
  2.Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015–2022CrossRef PubMed
  3.Machado EO, Taboada GF, Vieira Neto L, van Haute FR, Correa LL, Balarini GA, Shrank Y, Goulart M, Gadelha MR (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®. GH & IGF Res 18:389–393
  4.Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, Teramoto A, Tatsumi K, Tachibana K, Katsumata N, Horikawa R (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59:771–780CrossRef PubMed
  5.Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324–1330CrossRef PubMed
  6.Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529PubMed
  7.Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurg 33:610–618CrossRef
  8.Elias PCL, Lugao HB, Pereira MC, Machado HR, de Castro M, Moreira AC (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42:50–55CrossRef PubMed
  9.Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523–527CrossRef PubMed
  10.Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166–170CrossRef
  11.Clemmons DR, Conference P (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor Assays. Clin Chem 57:555–559CrossRef PubMed
  12.Bidlingmaier M, Freda PU (2010) Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. GH & IGF Res 20:19–25
  13.Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays - a 2009 update. GH & IGF Res 20:8–18
  14.Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz R, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89:2271–2274CrossRef PubMed PubMedCentral
  15.Boero L, Manavela M, Danilowicz K, Alfieri A, Ballarino MC, Chervin A, Garcia-Basavilbaso N, Glerean M, Guitelman M, Loto MG, Nahmias JA, Rogozinski AS, Servidio M, Vitale NM, Katz D, Day PF, Stalldecker G, Mallea-Gil MS (2012) Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary 15:466–471CrossRef PubMed
  16.Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen J, Uitterlinden P, Hofland LJ, Lamberts SWJ, van der Lely AJ, de Herder WW (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90:6480–6489CrossRef PubMed
  17.Sheppard M (2005) The critical parameters in GH excess. J Endocrinol Invest 28:92–95PubMed
  18.Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulinlLike growth factor-I. J Clin Endocrinol Metab 95:2486–2491CrossRef PubMed PubMedCentral
  19.Mercado M, Gonzalez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, Monteros ALE, Sosa E (2008) Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. Clin Endocrinol Metab 93:3411–3415CrossRef
  20.Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G (2006) Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 65:250–256CrossRef
  21.Meinhardt UJ, Ho KKY (2006) Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 65:413–422CrossRef
  22.Parkinson C, Renehan AG, Ryder WDJ, O’Dwyer ST, Shalet SM, Trainer PJ (2002) Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 57:59–64CrossRef
  23.Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52:181–185CrossRef PubMed
  24.Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G (2005) Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 63:342–349CrossRef
  25.Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720–724CrossRef PubMed
  
• 作者单位：Yasuyuki Kinoshita (1)
  Atsushi Tominaga (1)
  Satoshi Usui (1)
  Kazunori Arita (2)
  Tetsuhiko Sakoguchi (3)
  Kazuhiko Sugiyama (4)
  Kaoru Kurisu (1)
  
  1. Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
  2. Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan
  3. Department of Neurosurgery, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan
  4. Department of Clinical Oncology and Neuro-oncology Program, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurosurgery
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1437-2320

文摘

Discordant GH and IGF-1 levels after adenomectomy are well recognized in acromegalics. The aim of this study was to evaluate the clinical features and natural course of postoperative acromegaly associated with discordant GH and IGF-1 levels over a postoperative period. A total of 69 acromegalics underwent surgery with at least 1 year of follow-up and received 75-g oral glucose tolerance tests (OGTTs) at 3 months postoperatively. The patients were categorized into four groups according to the postoperative nadir GH levels and IGF-1 levels: controlled group (normal GH and normal IGF-1), high-IGF-1 group (normal GH and high IGF-1), high-GH group (high GH and normal IGF-1), and uncontrolled group (high GH and high IGF-1). The incidence of discordant GH and IGF-1 levels was 27.5 %: high-IGF-1 group = 10.1 % (n = 7) and high-GH group = 17.4 % (n = 12). All patients in the high-IGF-1 group exhibited a decline in the IGF-1 level after surgery, with normalization observed in 71.4 % of the patients without additional treatment (median 23 months). These subjects had preoperatively high IGF-1 levels despite not demonstrating higher GH levels than the patients in the controlled group. On the other hand, four patients in the high-GH group exhibited an elevated nadir GH level higher than 1.0 μg/L on repeated OGTTs after 3 months, and one patient experienced a recurrence of acromegaly. Patients in the high-IGF-1 group require no additional treatments, and their IGF-1 levels are likely to normalize within a few years. However, patients in the high-GH group should be carefully followed due to the possibility of recurrence.